Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anne Olland is active.

Publication


Featured researches published by Anne Olland.


Interactive Cardiovascular and Thoracic Surgery | 2013

Is radiofrequency ablation or stereotactic ablative radiotherapy the best treatment for radically treatable primary lung cancer unfit for surgery

Stéphane Renaud; Pierre-Emmanuel Falcoz; Anne Olland; Gilbert Massard

A best evidence topic was constructed according to a structured protocol. The question addressed was whether radiofrequency (RF) offers better results than stereotactic ablative therapy in patients suffering from primary non-small-cell lung cancer (NSCLC) unfit for surgery. Of the 90 papers found using a report search for RF, 5 represented the best evidence to answer this clinical question. Concerning stereotactic ablative therapy, of the 112 papers found, 10 represented the best evidence to answer this clinical question. A manual search of the reference lists permitted us to include seven more articles. The authors, journal, date, country of publication, study type, group studied, relevant outcomes and results of these papers are given. We conclude that, on the whole, the 23 retrieved studies clearly support the use of stereotactic ablative therapy rather than RF in patients suffering from primary NSCLC unfit for surgery. Indeed, stereotactic ablative therapy offered a 5-year local control rate varying between 83 and 89.5%, whereas the local control rate after RF ranges from 58 to 68%, with a short follow-up of ∼18 months. Furthermore, both overall survival and cancer-specific survival were better with stereotactic ablative therapy, with a 3-year overall survival ranging from 38 to 84.7% and the 3-year cancer-specific survival from 64 to 88%, whereas the 3-year OS, only reported in two studies, ranged from 47 to 74% for RF. Moreover, the post-interventional morbidity was superior for RF ranging from 33 to 100% (mainly composed by pneumothorax), whereas radiation pneumonitis and rib fracture, ranging, respectively, from 3 to 38% and 1.6 to 4%, were the primary complications following stereotactic ablative therapy. Hence, the current evidence shows that stereotactic ablative therapy is a safe and effective procedure and should be proposed first to patients suffering from primary NSCLC unfit for surgery. However, the published evidence is quite limited, mainly based on small studies of <100 patients. Moreover, so far there is no blind, prospective control, randomized study comparing these two techniques. Consequently, despite the encouragement of these preliminary results, they must be interpreted with caution.


British Journal of Cancer | 2015

KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer

Stéphane Renaud; Benoit Romain; Falcoz Pe; Anne Olland; Nicola Santelmo; Cécile Brigand; S. Rohr; Dominique Guenot; Gilbert Massard

Background:We evaluated KRAS (mKRAS (mutant KRAS)) and BRAF (mBRAF (mutant BRAF)) mutations to determine their prognostic potential in assessing patients with colorectal cancer (CRC) for lung metastasectomy.Methods:Data were reviewed from 180 patients with a diagnosis of CRC who underwent a lung metastasectomy between January 1998 and December 2011.Results:Molecular analysis revealed mKRAS in 93 patients (51.7%), mBRAF in 19 patients (10.6%). In univariate analyses, overall survival (OS) was influenced by thoracic nodal status (median OS: 98 months for pN−, 27 months for pN+, P<0.0001), multiple thoracic metastases (75 months vs 101 months, P=0.008) or a history of liver metastases (94 months vs 101 months, P=0.04). mBRAF had a significantly worse OS than mKRAS and wild type (WT) (P<0.0001). The 5-year OS was 0% for mBRAF, 44% for mKRAS and 100% for WT, with corresponding median OS of 15, 55 and 98 months, respectively (P<0.0001). In multivariate analysis, WT BRAF (HR: 0.005 (95% CI: 0.001–0.02), P<0.0001) and WT KRAS (HR: 0.04 (95% CI: 0.02–0.1), P<0.0001) had a significant impact on OS.Conclusions:mKRAS and mBRAF seem to be prognostic factors in patients with CRC who undergo lung metastasectomy. Further studies are necessary.


British Journal of Cancer | 2015

Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases

Stéphane Renaud; Pierre-Emmanuel Falcoz; Mickaël Schaeffer; Dominique Guenot; Benoit Romain; Anne Olland; Jérémie Reeb; Nicola Santelmo; Marie-Pierre Chenard; Michèle Legrain; Anne-Claire Voegeli; Michèle Beau-Faller; Gilbert Massard

Background:Identifying patients who will experience lung cancer recurrence after surgery remains a challenge. We aimed to evaluate whether mutant forms of epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene homolog (KRAS) (mEGFR and mKRAS) are useful biomarkers in resected non-small cell lung cancer (NSCLC).Methods:We retrospectively reviewed data from 841 patients who underwent surgery and molecular testing for NSCLC between 2007 and 2012.Results:mEGFR was observed in 103 patients (12.2%), and mKRAS in 265 (31.5%). The median overall survival (OS) and time to recurrence (TTR) were significantly lower for mKRAS (OS: 43 months; TTR: 19 months) compared with mEGFR (OS: 67 months; TTR: 24 months) and wild-type patients (OS: 55 months; disease-free survival (DFS): 24 months). Patients with KRAS G12V exhibited worse OS and TTR compared with the entire cohort (OS: KRAS G12V: 26 months vs Cohort: 60 months; DFS: KRAS G12V: 15 months vs Cohort: 24 months). These results were confirmed using multivariate analyses (non-G12V status, hazard ratio (HR): 0.43 (confidence interval: 0.28–0.65), P<0.0001 for OS; HR: 0.67 (0.48–0.92), P=0.01 for TTR). Risk of recurrence was significantly lower for non-KRAS G12V (HR: 0.01, (0.001–0.08), P<0.0001).Conclusions:mKRAS and mEGFR may predict survival and recurrence in early stages of NSCLC. Patients with KRAS G12V exhibited worse OS and higher recurrence incidences.


The Annals of Thoracic Surgery | 2014

Primary Lung Cancer in Lung Transplant Recipients

Anne Olland; Pierre-Emmanuel Falcoz; Nicola Santelmo; Romain Kessler; Gilbert Massard

Risk factors for lung cancer in lung transplant recipients are a history of smoking and immunosuppression, to which adds increasing use of lungs from donors with axa0smoking history. The three typical presentations are incidental diagnosis on the explanted lung, concerning less than 2%; lung cancer developing on the lung graft, accounting for less than 1%; and incidence of lung cancer on the native lung, estimated at 9%. Treatment along available guidelines may be hampered by decreased lungxa0function owing to chronic rejection or adverse effects of immunosuppression. Prognosis is comparable to a general population in resected stage I cancer and is less favorable in advanced stages.


European Journal of Cardio-Thoracic Surgery | 2014

High-emergency waiting list for lung transplantation: early results of a nation-based study.

Bastien Orsini; Edouard Sage; Anne Olland; Emmanuel Cochet; Mayeul Tabutin; Matthieu Thumerel; Florent Charot; Alain Chapelier; Gilbert Massard; Pierre Yves Brichon; François Tronc; Jacques Jougon; Marcel Dahan; Xavier Benoit D'Journo; Martine Reynaud-Gaubert; D. Trousse; C. Doddoli; Pascal Thomas

OBJECTIVESnThe high mortality rate observed on the regular waiting list (RWL) before lung transplantation (LTx) prompted the French organ transplantation authorities to set up in 2007 a dedicated graft allocation strategy, the so-called high-emergency waiting list (HEWL), for patients with an abrupt worsening of their respiratory function. This study reports on the early results of this new allocation system.nnnMETHODSnAmong 11 active French LTx programmes, 7 were able to provide full outcome data by 31 December 2011. The medical records of 101 patients who were listed on the HEWL from July 2007 to December 2011 were reviewed for an intention-to-treat analysis.nnnRESULTSnNinety-five patients received LTx within a median waiting time on the HEWL of 4 days (range 1-26), and 6 died before transplantation. Conditions were cystic fibrosis (65.2%), pulmonary fibrosis (24.8%), emphysema (5%) and miscellaneous (5%). The median age of the recipient was 30 years (range 16-66). Patients listed on the HEWL came from the RWL in 48.5% of the cases and were new patients in 51.5%. Forty-nine were placed under invasive ventilation and, in 26 cases, extracorporeal membrane oxygenation (ECMO) prior to transplantation was necessary as a complementary treatment. ECMO for non-intubated patients was performed in 6 cases. Eighty-one bilateral and 14 single LTx were performed, with an overall in-hospital mortality rate of 29.4%. One- and 3-year survival rates were 67.5 and 59%, respectively. Multivariate analysis shows that the use of ECMO prior to transplantation was the sole independent mortality risk factor (hazard ratio = 2.77 [95% CI 1.26-6.11]).nnnCONCLUSIONSnThe new allocation system aimed at lowering mortality on the RWL, but also offered an access to LTx for new patients with end-stage respiratory failure. The HEWL increased the likelihood of mortality after LTx, but permitted acceptable mid-term survival rates. The high mortality associated with the use of ECMO should be interpreted cautiously.


Interactive Cardiovascular and Thoracic Surgery | 2011

Should cystic fibrosis patients infected with Burkholderia cepacia complex be listed for lung transplantation

Anne Olland; Pierre-Emmanuel Falcoz; Romain Kessler; Gilbert Massard

A best evidence topic was constructed according to a structured protocol. The question addressed was whether lung transplantation remained a beneficial treatment for cystic fibrosis (CF) patients infected or colonized with Burkholderia cepacia complex (BCC) prior to lung transplantation (LTx). Of the 25 papers found using a report search, five presented the best evidence to answer the clinical question. The authors, journal, date and country of publication, study type, group studied, relevant outcomes and results of these papers are given. We conclude that, on the whole, the five studies were clearly in favor of maintaining access to LTx lists for BCC infected or colonized CF patients. In other words, access to LTx should not be denied to BCC infected CF patients in that the beneficial effects of LTx do not differ with respect to non-infected patients: comparison showed neither a difference in survival nor a higher mortality risk. However, results would differ for Burkholderia cenocepacia infected CF patients prior to LTx: both short- and long-term survival are significantly lower when B. cenocepacia infected patients are compared to other BCC infected patients or non-infected patients. Hence, current evidence shows that careful screening of all BCC suspected CF patients and risk-aware multidisciplinary management should be achieved before listing patients for LTx. This would allow identification of different bacterial species (in particular, B. cenocepacia) present and optimize lung transplantation survival outcomes.


Interactive Cardiovascular and Thoracic Surgery | 2013

Should mediastinal lymphadenectomy be performed during lung metastasectomy of renal cell carcinoma

Stéphane Renaud; Pierre-Emmanuel Falcoz; Anne Olland; Gilbert Massard

A best evidence topic was constructed according to a structured protocol. The question addressed was whether radical mediastinal lymphadenectomy should be performed during lung metastasectomy of renal cell carcinoma (RCC). Of the 13 papers found through a report search, seven represent the best evidence to answer this clinical question. The authors, journal, date, country of publication, study type, group studied, relevant outcomes and results of these papers are given. We conclude that on the whole, the seven-retrieved studies support the realization of systematic radical mediastinal lymphadenectomy. The published literature showed a prevalence of lymph node involvement (LNI) that approaches 30%. The majority of the studies conclude that LNI is a significant, independent prognostic of survival. Indeed, some authors did not report any 5-year survival in the case of LNI. On the contrary, however, a 5-year survival of ~50% was reported when no LNI was present. To date, the published data do not allow conclusions to be drawn regarding the prognosis of hilar vs mediastinal LNI: only one paper focused on the difference between hilar and mediastinal location and showed no difference. In addition, only one study has compared the survival of patients with or without lymphadenectomy, showing greater survival when mediastinal lymphadenectomy was performed. Despite the poor prognosis of patients with LNI, surgery seems to be the best treatment for potentially curative RCC with metastases. It is known that RCC metastases do not respond well to chemotherapy and radiotherapy. Indeed, reported 5-year survival rate ranged between 3 and 11% for non-operated patients. Consequently, resection must be as complete as possible and include a systematic total mediastinal lymphadenectomy, which will probably yield better loco-regional control and evaluation of prognostic factor. However, the published evidence remains quite limited and mainly based on retrospective studies on highly selected patients, with a low level of evidence. Indeed, most patients referred to surgery are younger, fitter, and have fewer metastases. Consequently, the survival gain could be biased, related more to the resectability and the good performance status rather to the resection itself. Consequently, although these preliminary results are interesting, they must be interpreted with caution.


Shock | 2016

An Intravenous Bolus of Epa: Dha 6: 1 Protects Against Myocardial Ischemia-Reperfusion-Induced Shock.

Mélanie Burban; Grégory Meyer; Anne Olland; François Severac; Blandine Yver; Florence Toti; Valérie B. Schini-Kerth; Ferhat Meziani; Julie Boisramé-Helms

Introduction: Enriching the diet with Omega-3 for several weeks improves myocardial resistance to ischemia-reperfusion (IR) in rats. However, patients with myocardial infarction requiring an emergency reperfusion cannot be pretreated with such a diet. The objective of our study was to describe the effects of an intravenous Omega-3 bolus before reperfusion in a rat model of myocardial IR. Methods: In a rat model of acute myocardial IR, an intravenous Omega-3 bolus (EPA:DHA 6:1), associated or not with iodinated contrast media, was administered after a 30-min ischemia, before reperfusion. Hemodynamic parameters were assessed. Circulating procoagulant microparticles were phenotyped. Vascular and heart inflammation, superoxide anion, and nitric oxide were measured. Ex vivo vascular reactivity was performed with a pharmacological selective inhibitor of inductible nitric oxide synthase. Cardiac troponin I (cTn-I) plasma levels were measured. Results: Compared with untreated IR rats, an Omega-3 bolus before reperfusion significantly decreased the IR syndrome, improving mean arterial pressure (114u200a±u200a9 vs. 61u200a±u200a17 mmHg 4 h after reperfusion, Pu200a<u200a0.05) and carotid blood flow, and decreasing plasma cTn-I levels after revascularization. These beneficial effects may be due to improved ex vivo mesenteric resistance artery sensitivity to phenylephrine, endothelial protection assessed by decreased endothelial CD54+ microparticle release (9.1u200a±u200a2.5 vs. 4.8u200a±u200a2.0u200anM Eq PhtdSer, Pu200a<u200a0.05) and reduced vascular inflammation and oxidative stress. Conclusions: In this rat model of myocardial IR, an intravenous Omega-3 bolus before reperfusion decreases IR-induced vascular failure and shock. These results open therapeutic perspectives as far as myocardial reperfusion process is concerned that deserve further explorations in humans.


Interactive Cardiovascular and Thoracic Surgery | 2015

Mediastinal downstaging after induction treatment is not a significant prognostic factor to select patients who would benefit from surgery: the clinical value of the lymph node ratio

Stéphane Renaud; Pierre-Emmanuel Falcoz; Anne Olland; Jérémie Reeb; Nicola Santelmo; Gilbert Massard

OBJECTIVESnMultimodal management of N2 non-small-cell lung cancer is still a matter of debate. In particular, the place of surgery for persistent N2 after induction treatment is controversial and surgery is usually reserved for patients experiencing a mediastinal downstaging (pN1 and pN0). We aimed to evaluate whether there might exist subgroups of pN2 according to the lymph node ratio (LNR).nnnMETHODSnBetween 1996 and 2012, we retrospectively reviewed the data from 152 potentially resectable cN2 patients who underwent an induction treatment before surgery.nnnRESULTSnThe median follow-up time was 32 months (2-112). The average age at the time of diagnosis was 58.52 ± 10.47 years. In univariate analysis, overall survival (OS) was significantly influenced by extracapsular spread (32 ± 5.33 vs 24 ± 12.73 months, P = 0.01), pN after surgery (65 ± 2.45 months for pN0, 44 ± 2.14 months for pN1 and 19 ± 1.72 months for pN2, P <0.0001) and LNR ≥ 1/3 (30 ± 3.77 months vs 16 ± 1.39 months, P <0.0001). When pN0 and pN1 patients were staged according to the LNR, the OS was divided by two for pN1 patients with an LNR ≥ 1/3 (48 ± 2.64 months vs 26 ± 5.65 months, P <0.001), whereas it decreased from 26 ± 0.87 to 15 ± 1.85 months (P <0.0001) for pN2 patients. OS was significantly better with adjuvant radio-chemotherapy than with chemotherapy or radiation therapy alone (P <0.0001). In multivariate analysis, mediastinal downstaging {Hazard Ratio (HR): 0.184 (95% confidence interval (CI): 0.084-0.403), P <0.0001} and LNR [HR: 0.359 (95% CI: 0.194-0.665], P = 0.001) remained significantly independent prognostic factors.nnnCONCLUSIONSnThe LNR may potentially identify subgroups of pN+ patients and allow enhancement of adjuvant treatments. Because pN2 with a low LNR had an equivalent survival to pN1 with a high LNR, mediastinal downstaging does not seem to be a sufficient prognostic factor to exclude patients after induction treatment from surgery.


Interactive Cardiovascular and Thoracic Surgery | 2015

The intrathoracic lymph node ratio seems to be a better prognostic factor than the level of lymph node involvement in lung metastasectomy of colorectal carcinoma

Stéphane Renaud; Pierre-Emmanuel Falcoz; Anne Olland; Mickaël Schaeffer; Jérémie Reeb; Nicola Santelmo; Gilbert Massard

OBJECTIVESnData on thoracic lymph node involvement (LNI) in lung metastasis of colorectal cancer (CRC) are conflicting, with a 5-year overall survival (OS) ranging from 6 to 40%. We aimed to evaluate whether there are subgroups of patients according to the lymph node ratio (LNR).nnnMETHODSnWe retrospectively reviewed the data from 106 patients who underwent a thoracic procedure for CRC lung metastasis with pathologically proven thoracic LNI.nnnRESULTSnIn the univariate analysis, the median OS was significantly poorer for a pN2 location of LNI (26 vs 16 months, P = 0.04), LNR ≥50% (30 vs 17 months, P = 0.005), high preoperative CEA (32 vs 16 months, P = 0.02), hepatic metastases (27 vs 11 months, P <0.0001) and disease-free survival < 24 months (32 vs 17 months, P = 0.05). When pN1 and pN2 patients were staged according to the LNR, the median OS was significantly better for an LNR <50% (27 vs 17 months for pN1, 32 vs 12 months for pN2, P = 0.01). In the multivariate analysis, a high preoperative CEA [hazard ratio (HR): 2.256 (1.051-4.841), P = 0.04], pN1 status [HR: 0.337 (0.162-0.7), P = 0.004] and the absence of hepatic metastases [HR: 0.395 (0.180-0.687), P = 0.02] remained significant prognostic factors. There was an upward trend for patients with LNR <50% [HR: 0.565 (0.296-1.082), P = 0.08]. Otherwise, low LNR was significantly associated with a decreased risk of loco-regional recurrence (HR: 0.36, 95% confidence intervals: 0.14-0.96, P = 0.04).nnnCONCLUSIONSnThe LNR seems to be a more reliable prognostic factor than LNI for CRC lung metastasis. Prospective studies are necessary.

Collaboration


Dive into the Anne Olland's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jérémie Reeb

University of Strasbourg

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Romain Kessler

University of Strasbourg

View shared research outputs
Top Co-Authors

Avatar

C. Bermudez

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

K. Dhital

St. Vincent's Health System

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge